Log in

NASDAQ:APLSApellis Pharmaceuticals Stock Price, Forecast & News

-0.01 (-0.04 %)
(As of 08/7/2020 04:00 PM ET)
Today's Range
Now: $27.10
50-Day Range
MA: $30.54
52-Week Range
Now: $27.10
Volume433,971 shs
Average Volume820,190 shs
Market Capitalization$2.05 billion
P/E RatioN/A
Dividend YieldN/A
Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is APL-2 that is in Phase III clinical trials for the treatment of geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria diseases; and in Phase II clinical trials for the treatment of cold agglutinin and warm antibody autoimmune hemolytic anemia diseases, as well as in Phase II clinical trials to treat four types of glomerular diseases, such as C3 glomerulopathy, IgA nephropathy, primary membranous nephropathy, and lupus nephritis. The company is also developing APL-9, which is in single ascending dose Phase I randomized, double-blind, and placebo-controlled clinical trials for intravenous administration in systemic indications. It has a risk-sharing collaboration agreement with SFJ Pharmaceuticals Group for the development of APL-2 in hematologic indications. Apellis Pharmaceuticals, Inc. was founded in 2009 and is headquartered in Crestwood, Kentucky.
Read More
Apellis Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.4Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.74 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:APLS



Sales & Book Value

Annual SalesN/A
Book Value$3.07 per share


Net Income$-304,710,000.00


Market Cap$2.05 billion
Next Earnings Date11/3/2020 (Estimated)
OptionableNot Optionable
-0.01 (-0.04 %)
(As of 08/7/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive APLS News and Ratings via Email

Sign-up to receive the latest news and ratings for APLS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Apellis Pharmaceuticals (NASDAQ:APLS) Frequently Asked Questions

How has Apellis Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Apellis Pharmaceuticals' stock was trading at $27.23 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, APLS shares have decreased by 0.5% and is now trading at $27.10.
View which stocks have been most impacted by Coronavirus

Do Wall Street analysts recommend investors buy shares of Apellis Pharmaceuticals?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Apellis Pharmaceuticals in the last year. There are currently 5 hold ratings, 9 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Apellis Pharmaceuticals

When is Apellis Pharmaceuticals' next earnings date?

Apellis Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Apellis Pharmaceuticals

How were Apellis Pharmaceuticals' earnings last quarter?

Apellis Pharmaceuticals Inc (NASDAQ:APLS) issued its quarterly earnings data on Friday, July, 31st. The company reported ($1.57) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($1.34) by $0.24.
View Apellis Pharmaceuticals' earnings history

What price target have analysts set for APLS?

15 brokerages have issued 12 month price objectives for Apellis Pharmaceuticals' shares. Their forecasts range from $29.00 to $86.00. On average, they expect Apellis Pharmaceuticals' stock price to reach $50.92 in the next twelve months. This suggests a possible upside of 87.9% from the stock's current price.
View analysts' price targets for Apellis Pharmaceuticals

Has Apellis Pharmaceuticals been receiving favorable news coverage?

Headlines about APLS stock have trended very negative recently, InfoTrie reports. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Apellis Pharmaceuticals earned a coverage optimism score of -3.4 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days.
View the latest news about Apellis Pharmaceuticals

Who are some of Apellis Pharmaceuticals' key competitors?

What other stocks do shareholders of Apellis Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Apellis Pharmaceuticals investors own include Fate Therapeutics (FATE), Opko Health (OPK), Axsome Therapeutics (AXSM), Corbus Pharmaceuticals (CRBP), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), AbbVie (ABBV), Amarin (AMRN), Aurinia Pharmaceuticals (AUPH) and Anavex Life Sciences (AVXL).

Who are Apellis Pharmaceuticals' key executives?

Apellis Pharmaceuticals' management team includes the following people:
  • Dr. Cedric Francois, Co-Founder, Pres, CEO & Director (Age 47)
  • Dr. Pascal Deschatelets, Co-Founder & COO (Age 49)
  • Mr. Timothy E. Sullivan, Chief Financial Officer (Age 48)
  • Dr. Federico Grossi M.D., Ph.D., Co-Founder and Exec. VP of Clinical Devel. & Medical Affairs (Age 45)
  • Mr. Ahmad Sadr, VP of Technical Operations

When did Apellis Pharmaceuticals IPO?

(APLS) raised $150 million in an initial public offering on Thursday, November 9th 2017. The company issued 10,700,000 shares at $13.00-$15.00 per share. Citigroup, J.P. Morgan and Evercore ISI served as the underwriters for the IPO.

What is Apellis Pharmaceuticals' stock symbol?

Apellis Pharmaceuticals trades on the NASDAQ under the ticker symbol "APLS."

Who are Apellis Pharmaceuticals' major shareholders?

Apellis Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Jennison Associates LLC (2.81%), Victory Capital Management Inc. (2.60%), Candriam Luxembourg S.C.A. (1.60%), Rhenman & Partners Asset Management AB (0.22%), Swiss National Bank (0.18%) and Alps Advisors Inc. (0.14%). Company insiders that own Apellis Pharmaceuticals stock include Alec Machiels, Cedric Francois, David O Watson, Federico Grossi, Morningside Venture Investment, Pascal Deschatelets and Timothy Eugene Sullivan.
View institutional ownership trends for Apellis Pharmaceuticals

Which institutional investors are selling Apellis Pharmaceuticals stock?

APLS stock was sold by a variety of institutional investors in the last quarter, including Alps Advisors Inc., Strs Ohio, UBS Group AG, SG Americas Securities LLC, and Virtus ETF Advisers LLC. Company insiders that have sold Apellis Pharmaceuticals company stock in the last year include Alec Machiels, Cedric Francois, Federico Grossi, and Pascal Deschatelets.
View insider buying and selling activity for Apellis Pharmaceuticals

Which institutional investors are buying Apellis Pharmaceuticals stock?

APLS stock was acquired by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Victory Capital Management Inc., Rhenman & Partners Asset Management AB, Jennison Associates LLC, Rafferty Asset Management LLC, Swiss National Bank, Mackay Shields LLC, and Principal Financial Group Inc.. Company insiders that have bought Apellis Pharmaceuticals stock in the last two years include Morningside Venture Investment, and Timothy Eugene Sullivan.
View insider buying and selling activity for Apellis Pharmaceuticals

How do I buy shares of Apellis Pharmaceuticals?

Shares of APLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Apellis Pharmaceuticals' stock price today?

One share of APLS stock can currently be purchased for approximately $27.10.

How big of a company is Apellis Pharmaceuticals?

Apellis Pharmaceuticals has a market capitalization of $2.05 billion. The company earns $-304,710,000.00 in net income (profit) each year or ($4.64) on an earnings per share basis. Apellis Pharmaceuticals employs 87 workers across the globe.

What is Apellis Pharmaceuticals' official website?

The official website for Apellis Pharmaceuticals is www.apellis.com.

How can I contact Apellis Pharmaceuticals?

Apellis Pharmaceuticals' mailing address is 100 FIFTH AVENUE, WALTHAM MA, 02451. The company can be reached via phone at 617-977-5700 or via email at [email protected]

This page was last updated on 8/9/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.